Literature DB >> 28096060

Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy.

Sara Emerenziani1, Livia Biancone2, Michele Pier Luca Guarino3, Paola Balestrieri3, Elisa Stasi2, Mentore Ribolsi3, Maria Paola Rescio3, Annamaria Altomare3, Silvia Cocca3, Francesco Pallone2, Michele Cicala3.   

Abstract

BACKGROUND: Altered body composition is frequently observed in Crohn's disease (CD) patients. AIMS: To investigate the nutritional status, and the effect of different therapeutic regimes in adult CD patients.
METHODS: Fat free mass (FFM) and BIA-derived phase angle (PhA) were assessed in 45 CD patients, 22 on conventional therapy (CT) and 23 on maintenance therapy with infliximab (MT). Nutritional status was also assessed in 12 CD patients before and following the induction protocol with infliximab. BIA data of CD patients were compared with those of 20 healthy asymptomatic volunteers. In CD patients C Reactive Protein (CRP) and albuminaemia dosage were obtained.
RESULTS: The mean values of PhA and of FFM were significantly lower in CT patients when compared with control group and MT patients. Following infliximab treatment FFM increased, although not significantly, while mean phase angle value significantly increased from 4.6±0.3 to 6.2±0.4 (p<0.05). CRP was significantly lower in MT patients compared to that in CT patients.
CONCLUSION: CD patients on conventional therapy showed a lower FFM and a lower mean phase angle score compared to those on infliximab therapy. Following infliximab treatment the mean phase angle score normalized. PhA is a reliable nutritional indicator in IBD patients and could be considered as an additional tool for assessing response to treatment.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Biologic and conventional therapies; Body composition; Crohn’s disease; Malnutrition; Nutritional status

Mesh:

Substances:

Year:  2016        PMID: 28096060     DOI: 10.1016/j.dld.2016.12.026

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

Review 1.  European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.

Authors:  Stephan C Bischoff; Rocco Barazzoni; Luca Busetto; Marjo Campmans-Kuijpers; Vincenzo Cardinale; Irit Chermesh; Ahad Eshraghian; Haluk Tarik Kani; Wafaa Khannoussi; Laurence Lacaze; Miguel Léon-Sanz; Juan M Mendive; Michael W Müller; Johann Ockenga; Frank Tacke; Anders Thorell; Darija Vranesic Bender; Arved Weimann; Cristina Cuerda
Journal:  United European Gastroenterol J       Date:  2022-08-12       Impact factor: 6.866

2.  Phase Angle as a Comprehensive Tool for Nutritional Monitoring and Management in Patients with Crohn's Disease.

Authors:  Ziheng Peng; Duo Xu; Yong Li; Yu Peng; Xiaowei Liu
Journal:  Nutrients       Date:  2022-05-28       Impact factor: 6.706

3.  Bioelectrical Impedance Phase Angle as an Indicator of Malnutrition in Hospitalized Children with Diagnosed Inflammatory Bowel Diseases-A Case Control Study.

Authors:  Paweł Więch; Mariusz Dąbrowski; Dariusz Bazaliński; Izabela Sałacińska; Bartosz Korczowski; Monika Binkowska-Bury
Journal:  Nutrients       Date:  2018-04-17       Impact factor: 5.717

Review 4.  Nutritional Aspects in Inflammatory Bowel Diseases.

Authors:  Paola Balestrieri; Mentore Ribolsi; Michele Pier Luca Guarino; Sara Emerenziani; Annamaria Altomare; Michele Cicala
Journal:  Nutrients       Date:  2020-01-31       Impact factor: 5.717

Review 5.  Changes in Anthropometric Parameters After Anti-TNFα Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Authors:  Faizan Mazhar; Vera Battini; Marco Pozzi; Elena Invernizzi; Giulia Mosini; Michele Gringeri; Annalisa Capuano; Cristina Scavone; Sonia Radice; Emilio Clementi; Carla Carnovale
Journal:  BioDrugs       Date:  2020-10       Impact factor: 5.807

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.